Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma

Cancer Letters

Volumn 193, Issue 2, 2003, Pages 199-205

  Anzola, Mónica ^a   Cuevas, Nerea ^a   López Martínez, Mónica ^a   Saiz, Alberto ^b   Burgos, Juan José ^b   Martínez De Pancorbo, Marian ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

Author keywords

Codon 72 polymorphism; Hepatitis C virus; Hepatocellular carcinoma; Loss of heterozygosity; p53

Indexed keywords

PROTEIN P53;

ARTICLE; CODON; CONTROLLED STUDY; DNA POLYMORPHISM; EVALUATION; GENOTYPE; HEPATITIS C VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; VIRUS CARRIER;

HEPATITIS C VIRUS; MARTES PENNANTI;

EID: 0037466368     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00046-6     Document Type: Article

References (34)

1. DiBesceglie A.M., Rustgi V.K., Hoofnagle J.H., Dusheiko G.M., Lotze M.T. Conference NIH: hepatocellular carcinoma. Ann. Intern. Med. 108:1988;390-401.
2. Tsukuma H., Hiyama T., Tanaka S., Nakao M., Yabuuchi T., Kitamura T., Nakanishi K., Fujimoto I., Inoue A., Yamazaki H. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N. Engl. J. Med. 328:1993;1797-1801.
3. Yu M.C., Mack T., Hanisch R., Peters R.L., Henderson B.E., Pike M.C. Hepatitis, alcohol consumption, cigarette smoking, and hepatocellular carcinoma in Los Angeles. Cancer Res. 43:1983;6077-6079.
4. Vogelstein B., Kinzler K. P53 function and dysfunction. Cell. 70:1992;523-526.
5. Kern S.E., Kinzler K.W., Bruskin A., Jarosz D., Friedman P., Prives C., Vogelstein B. Identification of p53 as a sequence-specific DNA-binding protein. Science. 252:1991;1708-1711.
6. Levine A.J., Momand J., Finlay C.A. The p53 tumour suppressor gene. Nature. 351:1991;453-456.
7. Oren M. Relationship of p53 to the control of apoptotic cell death. Semin. Cancer Biol. 5:1994;221-227.
8. Oda T., Tsuda H., Scarpa A., Sakamoto M., Hirohashi S. p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res. 52:1992;6358-6364.
9. Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 350:1991;427-428.
10. Murakami Y., Hayashi K., Hirohashi S., Sekiya T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res. 51:1991;5520-5525.
11. Yu M.W., Yang S.Y., Chiu Y.H., Chiang Y.C., Liaw Y.F., Chen C.J.A. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology. 29:1999;697-702.
12. Matlashewski G.J., Tuck S., Pim D., Lamb P., Schneider J., Crawford L.V. Primary structure polymorphism at amino acid residue 72 of human p53. Mol. Cell Biol. 7:1987;961-963.
13. Storey A., Thomas M., Kalita A., Harwood C., Gardiol D., Mantovani F., Breuer J., Leigh I.M., Matlashewski G., Banks L. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 393:1998;229-234.
14. Gottschlich S., Maune S., Preugschat J., Hoffmann M., Werner J.A., Maass J.D., Görögh T., Heidorn K., Rudert H. p53 analysis of laryngeal cancer in exon 4 to 9. Anticancer Res. 20:2000;2613-2616.
15. Wang N.M., Tsai C.H., Yeh K.T., Chen S.J., Chang J.G. P53 codon 72Arg polymorphism is not a risk factor for carcinogenesis in the Chinese. Int. J. Mol. Med. 4:1999;249-252.
16. Sourvinos G., Rizos E., Spandidos D.A. p53 Codon 72 polymorphism is linked to the development and not the progression of benign and malignant laryngeal tumours. Oral Oncol. 37:2001;572-578.
17. Kawajiri K., Nakachi K., Imai K., Watanabe J., Hayashi S. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis. 14:1993;1085-1089.
18. Sjalander A., Birgander R., Hallmans G., Cajander S., Lenner P., Athlin L., Beckman G., Beckman L. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis. 17:1996;1313-1316.
19. Sjalander A., Birgander R., Athlin L., Stenling R., Rutegard J., Beckman L., Beckman G. P53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis. 16:1995;1461-1464.
20. Okada F., Shiraki T., Maekawa M., Sato S. A p53 polymorphism associated with increased risk of hepatitis C virus infection. Cancer Lett. 172:2001;137-142.
21. Beckman G., Birgander R., Sjalander A., Saha N., Holmberg P.A., Kivela A., Beckman L. Is p53 polymorphism maintained by natural selection? Hum. Hered. 44:1994;266-270.
22. Smith J.C., Newton C.R., Alves A., Anwar R., Jenner D., Markham A.F. Highly polymorphic minisatellite DNA probes: further evaluation for individual identification and paternity testing. J. Forensic Sci. 30:1990;3-18.
23. Giannoudis A., Graham D.A., Southern S.A., Herrington C.S. p53 codon 72 Arg/Pro polymorphism is not related to HPV type or lesion grade in low-and high-grade squemous intra-epithelial lesions and invasive squemous carcinoma of the cervix. Int. J. Cancer. 83:1999;66-69.
24. Hayes V.M., Hofstra R.M.W., Buys C.H.C.M., Hollema H., van der Zee A.T.G.J. Homozygous arginine-72 in wild type p53 and risk of cervical cancer. Lancet. 352:1998;1756-1758.
25. Lanham S., Campbell I., Watt P., Gornall R. p53 polymorphism and risk of cervical cancer. Lancet. 352:1998;1631.
26. Rosenthal A.N., Ryan A., Al-Jehani R., Storey A., Harwood C.A., Jacobs I.J. p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet. 352:1998;871-875.
27. Ara S., Lee P.S., Hansen M.F., Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res. 18:1990;4961.
28. Fujimori M., Tokino T., Hino O., Kitagawa T., Imamura T., Okamoto E., Mitsunobu M., Ishikawa T., Nakagama H., Harada H. Allelotype study of primary hepatocellular carcinoma. Cancer Res. 51:1991;89-93.
29. Nose H., Imazeki F., Ohto M., Omata M. p53 gene mutations and 17 p allelic deletions in hepatocellular carcinoma from Japan. Cancer. 72:1993;355-360.
30. Marin M.C., Jost C.A., Brooks L.A., Irwin M.S., O'Nions J., Tidy J.A., James N., McGregor J.M., Harwood C.A., Yulug I.G., Vousden K.H., Allday M.J., Gusterson B., Ikawa S., Hinds P.W., Crook T., Kaelin W.G. A common polymorphism acts as a negative modifier of mutant p53 behaviour. Nat. Genet. 25:2000;47-54.
31. Brooks L.A., Tidy J.A., Gusterson B., Hiller L., O'Nions J., Gasco M., Marin M.C., Farrell P.J., Kaelin W.G., Crook T. Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res. 60:2000;6875-6877.
32. DiComo C.J., Gaiddon C., Prives C. P73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. Cell Biol. 19:1999;1438-1449.
33. Honda M., Kaneko S., Shimazaki T., Matsushita E., Kobayashi K., Ping L.H., Zhang H.C., Lemon S.M. Hepatitis C virus core protein induces apoptosis and impairs cell-cycle regulation in stably transformed Chinese hamster ovary cells. Hepatology. 31:2000;1351-1359.
34. Majumder M., Ghosh A.K., Steel R., Ray R., Ray R.B. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J. Virol. 75:2001;1401-1407.